Nexavar, the blockbuster cancer drug sold by Bayer and Onyx Pharmaceuticals, has failed again in a trial for a new indication.
An interesting development in this age of Irish-fueled tax inversion deals, the Mayo Clinic and Enterprise Ireland have begun a 5-year collaboration to advance med tech innovation.
Keryx Biopharmaceuticals' in-development Zerenex helped reduce dangerous buildups of phosphorus in patients on kidney dialysis, meeting its goals in a Phase III study as the company awaits final word from the FDA.
Researchers are hoping to get into the clinic in the next three to 5 years with a self-assembling nanoparticle that targets tumors. The idea behind the technology is to make cancer cells more identifiable when using magnetic resonance imaging screening.
A record-breaking material discovered last year by Swedish researchers has passed another milestone for drug delivery, showing it can hold poorly soluble drugs and, down the road, deliver them with a fast dissolution rate.
A platelet bioreactor was developed by researchers at Brigham and Women's Hospital.
The psychiatric sector received a big boost this week when the Broad Institute was given $650 million to investigate the genetic causes of mental illnesses such as schizophrenia and bipolar disorder. And the impact of the work is set to extend far beyond Cambridge, with Broad making the data available to researchers around the world.
The rise of electronic health records was heralded as a step toward the merging of patient care and research, a scenario in which data from the day-to-day of healthcare is gathered to inform treatment and drug development. But a study in the United Kingdom suggests that while technology can now facilitate this vision, the path is blocked by another barrier: red tape.
The $40 million Department of Defense research program into restoring memory will use NeuroPace's implantable neurostimulator, a move that the company said could help it expand the product's indications beyond epilepsy.
A new three-drug combo treatment for tuberculosis better eradicated the disease than standard therapy in a midstage trial, showing particular promise for patients with HIV as it rolls into Phase III development.